Cabaletta Bio Inc logo

CABA

Cabaletta Bio Inc

$1.38

Earnings Summary

Revenue
$0Mn
Net Profits
$-12.95Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Cabaletta Bio Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Cabaletta Bio Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Cabaletta Bio Inc’s net profit fell -33.44% since last year same period to $-12.95Mn in the Q1 2022. On a quarterly growth basis, Cabaletta Bio Inc has generated 6.78% jump in its net profits since last 3-months.

Net Profit Margins:

Cabaletta Bio Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Cabaletta Bio Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cabaletta Bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.5
EPS Estimate Current Year
-0.5

Highlights

EPS Estimate Current Quarter:

Cabaletta Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.5 - a 16.67% jump from last quarter’s estimates.

EPS Estimate Current Year:

Cabaletta Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.5.

Key Ratios

Key ratios of the Cabaletta Bio Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.45
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.52
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Cabaletta Bio Inc’s earning per share (EPS) fell -9.76% since last year same period to -0.45 in the Q1 2022. This indicates that the Cabaletta Bio Inc has generated -9.76% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cabaletta Bio Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cabaletta Bio Inc’s return on equity (ROE) stands at -0.52.

Dividend Per Share (DPS):

Cabaletta Bio Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.6
-0.45
25%

Company Information

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Organisation
Cabaletta Bio Inc
Employees
34
Industry
Health Technology